CRISPR Therapeutics AG (CRSP) – What Are Researchers Thinking About This Stock?

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $65.75.

Several research analysts recently commented on the stock. William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. UBS Group began coverage on shares of CRISPR Therapeutics in a research note on Thursday. They issued a “neutral” rating and a $52.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $51.52 on Friday. The stock has a fifty day moving average of $55.07 and a 200-day moving average of $53.24. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $75.06. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. As a group, sell-side analysts forecast that CRISPR Therapeutics will post -4.48 EPS for the current fiscal year.

Insider Activity

In other news, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director directly owned 16,637 shares in the company, valued at approximately $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 10,400 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $60.24, for a total value of $626,496.00. Following the sale, the general counsel owned 94,784 shares in the company, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 31,207 shares of company stock worth $1,780,008. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its holdings in shares of CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Sunbelt Securities Inc. boosted its position in shares of CRISPR Therapeutics by 4.5% in the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company’s stock valued at $373,000 after acquiring an additional 336 shares during the period. D.A. Davidson & CO. grew its stake in CRISPR Therapeutics by 5.9% during the first quarter. D.A. Davidson & CO. now owns 6,324 shares of the company’s stock valued at $301,000 after acquiring an additional 353 shares in the last quarter. Kestra Advisory Services LLC grew its stake in CRISPR Therapeutics by 2.0% during the first quarter. Kestra Advisory Services LLC now owns 21,052 shares of the company’s stock valued at $1,001,000 after acquiring an additional 416 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in CRISPR Therapeutics by 6.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,202 shares of the company’s stock valued at $390,000 after acquiring an additional 489 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.